2493. Real-World Utilization of Ibalizumab (IBA) Without an Optimized Background Regimen (OBT)

BACKGROUND: It is difficult to treat multidrug-resistant (MDR) human immunodeficiency virus (HIV). Trogarzo® (ibalizumab) a novel monoclonal antibody was approved in 2018 for heavily treatment-experienced HIV patients. Data support IBA use with at least one fully active agent, an OBR. Real-world IBA...

Full description

Saved in:
Bibliographic Details
Published in:Open Forum Infect Dis
Main Authors: Bouchard, Jeannette, Derrick, Caroline, Horvath, Joseph
Format: Artigo
Language:Inglês
Published: Oxford University Press 2019
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6809681/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2171
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items